Pirfenidone is InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis to reduce decline in lung function.

FORBES: Magazine Article

InterMune announced that the FDA has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee meeting to review their New Drug Application for pirfenidone.

FORBES: Magazine Article

The proposed trade name for pirfenidone is Esbriet.

FORBES: Magazine Article